Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease

Current Opinion in Investigational Drugs

Volumn 10, Issue 3, 2009, Pages 239-244

  Colatsky, T J ^a  

^a GainStage Biosciences   (United States)

Author keywords

Cardiovascular risk; Carotid intima media thickness; ENHANCE trial; Ezetimibe; LDL cholesterol; Simvastatin; Surrogate marker; Vytorin

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MEDICAL DECISION MAKING; MONOTHERAPY; REVIEW; VALIDITY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA;

EID: 62249093192     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG: Biomarkers in the prevention and treatment of atherosclerosis: Need, validation, and future. Pharmacol Rev (2007) 59(1):40-53. • Comprehensive review providing an introduction to the general area of atherosclerosis biomarkers in drug development and medical practice.
2. Glassberg H, Rader DJ: Management of lipids in the prevention of cardiovascular events. Annu Rev Med (2008) 59:79-94.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110(2):227-239.
4. Smith EE, Abdullah AR, Amirfarzan H, Schwamm LH: Serum lipid profile on admission for ischemic stroke: Failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Neurology (2007) 68(9):660-665.
5. Patek JV, Kirby M, Hughes EA: The lipid audit: Analysis of lipid management in two centres in Britain 2003. Brit J Cardiol (2004) 11(3):214-217.
6. Brown WV: Novel approaches to lipid lowering: What is on the horizon? Am J Cardiol (2001) 87(5A):23B-27B.
7. Levy E, Spahis S, Sinnett D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA: Intestinal cholesterol transport proteins: An update and beyond. Curr Opin Lipidol (2007) 18(3):310-318.
8. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 40(12):2125-2134.
9. Sacks FM: Low-density lipoprotein lowering therapy: An analysis of the options. J Am Coll Cardiol (2002) 40(12):2135-2138.
10. Grigore L, Norata GD, Catapano AL: Combination therapy in cholesterol reduction: Focus on ezetimibe and statins. Vasc Health Risk Manag (2008) 4(2):267-278. •• Excellent overview of ezetimibe, its pharmacology and its use in the treatment of dyslipidemia.
11. Davies JP, Ioannou YA: Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterolsensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage activating protein. J Biol Chem (2006) 275(32):24367-24374.
12. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L et al: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303(5661):1201-1204. •• One of several key papers elucidating the target for the site of action of ezetimibe.
13. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA et al: Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem (2004) 279(32):33586-33592. •• One of several key papers elucidating the target for the site of action of ezetimibe.
14. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN: Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos (2002) 30(4):430-437.
15. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc (2005) 80(5):587-595.
16. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM: Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes Vasc Dis Res (2006) 3(2):93-102.
17. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, Shah S, Sidisin M, Cho M, Kush D, Mitchel Y: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol (2004) 93(12):1481-1486.
18. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E: Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol (2007) 99(5):673-680.
19. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol (2006) 47(8):1584-1587.
20. Thayer AM: Stay with statins. American Chemical Society, Washington DC, USA. pubs.acs.org/cen/news/86/i14/8614news1.html
21. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D et al: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 358(14):1431-1443. •• Publication of the results of the ENHANCE trial.
22. Brown GB, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med (2008) 358(14):1504-1507. •• Editorial response to the publication of the ENHANCE trial, providing the foundation for the challenge to the lipid hypothesis.
23. Drazen JM, Jarcho JA, Morrissey S, Curfman GD: Cholesterol lowering and ezetimibe. N Engl J Med (2008) 358(14):1507-1508. •• This reference, along with references [24-28], include a series of letters to the editor in response to the publication of the ENHANCE trial results. These letters provide a variety of viewpoints from medical practitioners and other experts on the trial design, analysis of data and investigational methodologies.
24. Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med (2008) 358(14):1504-1507.
25. Eichhorn EJ: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 359(5):529-530, author reply 532.
26. Steinberg D: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 359(5):529, author reply 532.
27. Diamond GA, Kaul S: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 359(5):530, author reply 532.
28. Connor WE: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 359(5):530, author reply 532-533.
29. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med (1998) 128(4):262-269.
30. Persson J, Formgren J, Israelsson B, Berglund G: Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. Arterioscler Thromb (1994) 14(2):261-264.
31. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med (1999) 340(1):14-22. •• Landmark paper describing the relationship between carotid IMT and cardiovascular risk.
32. Yanai H, Yoshida H, Tomono Y, Tada N: Atherosclerosis imaging in statin intervention trials. Q J Med (2007) 100(5):253-262. •• Thorough review of imaging data from available lipid-lowering drug trials.
33. Espeland MA, O'Leary DH, Terry JT, Morgan T, Evans G, Mudra H: Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med (2005) 6(1):3. • Presents a statistically reasoned case for accepting carotid IMT as a validated marker for coronary atherosclerosis.
34. Boissel JP, Collet JP, Moleur P, Haugh M: Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol (1992) 43(3):235-244.
35. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med (1989) 8(4):431-440.
36. Lesko LJ, Atkinson AJ Jr: Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxico (2001) 41:347-366. •• Along with references [29] and [30], this paper provides the scientific and statistical rationales for qualifying, validating and using surrogate markers in drug development.
37. Ubels FL, Muntinga JH, van Doormaal JJ, Reitsma WD, Smit AJ: Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics. Atherosclerosis (2001) 154(1):155-161. •• Describes a dissociation between the lipid-lowering effects of statins and carotid IMT changes in statin-naïve patients compared with long-term statin users.
38. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G: The early effect of lipid lowering treatment on carotid and femoral intima-media thickness (IMT). Eur J Vasc Endovasc Surg (2002) 23(4):358-364.
39. Byington RP, Furberg CD, Crouse JR 3rd, Espeland MA, Bond MG: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol (1995) 76(9):54C-59C.
40. Reid JA, Wolsley C, Lau LL, Hannon RJ, Lee B, Young IS, Soong CV: The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur J Vasc Endovasc Surg (2005) 30(5):464-468.
41. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN: ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation (2002) 106(16):2055-2060.
42. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation (2004) 110(23):3512-3517.
43. Kablak-Ziembicka A, Przewlocki T, Tracz W, Pieniazek P, Musialek P, Sokolowski A: Gender differences in carotid intima-media thickness in patients with suspected coronary artery disease. Am J Cardiol (2005) 96(9):1217-1222.
44. Vicenzini E, Ricciardi MC, Puccinelli F, Altieri M, Vanacore N, Di Piero V, Lenzi GL: Common carotid artery intima-media thickness determinants in a population study. J Ultrasound Med (2007) 26(4):427-432.
45. NCT00202878: IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin (study P04103). Schering-Plough Corp, Kenilworth, NJ, USA (2008). www.clinicaltrials.gov/ct2/show/NCT00202878?term=improve-it&rank=1
46. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 359(21):2195-2207. •• Key clinical outcomes study (JUPITER) demonstrating that the administration of a statin to patients with elevated CRP and normal-to-low cholesterol levels had beneficial effects on cardiovascular morbidity and mortality.
47. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti A, MacFadyen J, Nordestgaard BG et al: Rosuvastatin in the prevention of cardiovascular events among 17,802 men and women with elevated levels of C-reactive protein: The JUPITER Trial. American Heart Association Scientific Sessions (2008):Abs 161.
48. Tedgui A, Mallat Z: Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev (2006) 86(2):515-581. •• Comprehensive review of the role of inflammation and cytokines in atherosclerosis.
49. Hanson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 352(16):1685-1695.